Lactate-GPR81-FARP1-Rac1 Axis Enables Insulin-Independent Glucose Uptake

Study Background and Research Question

Insulin is the principal hormone driving glucose uptake in skeletal muscle and adipose tissues, acting through the AKT signaling pathway to translocate the glucose transporter GLUT4 to the plasma membrane. However, clinical and physiological observations show that glucose disposal persists even under insulin-deficient or insulin-resistant states, particularly during and after exercise. This phenomenon has prompted the search for alternative, insulin-independent mechanisms that modulate glucose uptake—a research question of significant relevance for metabolic disease management (Cell Research, 2026).

L-lactate, a metabolite produced in large quantities by skeletal muscle during vigorous exercise, is known to accumulate both systemically and locally. While increased plasma lactate correlates with improved glycemic control post-exercise, the underlying molecular mechanisms have not been fully elucidated. The central question addressed by Niu et al. (2026) is whether lactate can directly drive glucose uptake by skeletal muscle through an insulin-independent pathway, and if so, what molecular components mediate this effect.

Key Innovation from the Reference Study

The pivotal innovation of this study is the identification of a signaling axis wherein extracellular lactate activates the G protein-coupled receptor GPR81 (also known as HCAR1) on skeletal muscle cells. Upon activation, GPR81 recruits FARP1, a RhoGEF family member, which in turn activates the small GTPase Rac1. This cascade promotes the translocation of GLUT4 to the plasma membrane, facilitating glucose uptake independent of canonical insulin-AKT signaling (Cell Research, 2026).

This work establishes that lactate is not merely a byproduct of anaerobic metabolism or a metabolic substrate, but also a signaling molecule capable of driving muscle glucose uptake via a distinct, insulin-independent pathway. The study also demonstrates that this mechanism is physiologically relevant, particularly in the context of exercise-induced metabolic adaptation and glucose homeostasis.

Methods and Experimental Design Insights

The authors employed a multifaceted approach combining genetic, pharmacological, and physiological methods in both murine models and primary muscle cell systems:

• Genetic Manipulation: Muscle-specific knockout mice for LDHA (lactate dehydrogenase A, the key enzyme for lactate production) were used to assess the systemic effects of reduced lactate on glucose tolerance and muscle glucose uptake.
• Pharmacological Modulation: Exogenous lactate was administered to wild-type mice, while GPR81 knockout and overexpression models were leveraged to dissect the receptor’s role. Pharmacological agonists and antagonists of GPR81 were also utilized.
• Cellular Assays: Primary skeletal muscle cells were subjected to lactate stimulation. The role of downstream effectors was examined via siRNA-mediated knockdown of FARP1 and Rac1.
• Biochemical and Imaging Techniques: GLUT4 translocation was quantified using immunofluorescence and biochemical fractionation. Glucose uptake was measured using radiolabeled tracers, while Rac1 activation was monitored via pull-down assays (Cell Research, 2026).
• Human Association Studies: The study further analyzed gene expression datasets following exercise and conducted genetic association studies linking GPR81 variants to fasting insulin levels in humans.

Protocol Parameters

• glucose uptake assay | 2-deoxyglucose uptake, nM/min/mg protein | skeletal muscle cells, in vivo mouse muscle | quantifies insulin-independent glucose uptake | paper
• lactate administration | 1–3 g/kg, i.p. | mouse in vivo models | mimics exercise-induced lactate surge | paper
• GPR81 agonist/antagonist treatment | micromolar range, cell culture | dissecting GPR81 receptor function | validates receptor specificity | paper
• Rac1 activation assay | GST-PAK pull-down, arbitrary units | muscle lysates | measures GTP-bound active Rac1 | paper
• NSC23766 trihydrochloride (Rac1 inhibitor) | 10–50 µM, cell culture | negative control for Rac1-dependent uptake | workflow_recommendation

Core Findings and Why They Matter

The study’s core findings are as follows:

• Lactate drives glucose uptake in skeletal muscle independently of insulin. Loss of LDHA, and thus lactate production, impairs glucose tolerance and reduces muscle glucose uptake in mice. Conversely, pharmacological or genetic upregulation of lactate improves glycemic control (Cell Research, 2026).
• GPR81 is essential for lactate-mediated glucose regulation. Muscle-specific GPR81 knockout mice show worsened glucose tolerance, while its overexpression or agonism enhances glucose uptake and metabolism.
• FARP1 and Rac1 are required effectors downstream of GPR81. FARP1 is recruited to GPR81 upon lactate stimulation, activating Rac1. Silencing either FARP1 or Rac1 abrogates both GLUT4 translocation and the glucose uptake response to lactate.
• GLUT4 translocation occurs independently of AKT signaling. Lactate-GPR81 signaling does not activate AKT, highlighting true insulin independence.
• Exercise upregulates LDHA, GPR81, and FARP1 expression in muscle. This suggests that exercise-induced lactate surge is physiologically harnessed for enhanced glucose disposal.
• Human genetic studies link GPR81 variants to fasting insulin levels. This strengthens the translational relevance of the pathway.

Collectively, these findings provide a mechanistic explanation for the exercise-induced improvement in glucose tolerance observed in both healthy and diabetic individuals, independent of insulin secretion (Cell Research, 2026).

Comparison with Existing Internal Articles

A series of internal articles have explored the use of Rac1 pathway inhibitors, notably NSC23766 trihydrochloride, in cellular and cancer research:

• "NSC-23766 trihydrochloride: Rac GTPase Inhibitor for Precision Cell Signaling" details how this small molecule selectively inhibits Rac1-GEF interactions, enabling the dissection of Rac1’s role in apoptosis and cell cycle regulation in cancer models.
• "NSC-23766: Selective Rac1-GEF Inhibitor for Precision Cancer Research" highlights the utility of NSC-23766 for probing Rac1 signaling in breast cancer, particularly for studying apoptosis induction and cell cycle arrest mechanisms.
• "Unveiling New Frontiers in Rac1 Pathway Inhibition" explores the broader implications of Rac1 inhibition in stem cell biology and cancer research.

The present study extends these themes by demonstrating Rac1’s critical role in non-cancer settings, specifically metabolic regulation and insulin-independent glucose uptake. While prior articles focus on Rac1 as a target for cell cycle arrest and apoptosis in oncology, this paper positions Rac1 activation as beneficial in metabolic contexts—highlighting the importance of context-specific modulation of this GTPase. Thus, Rac1 pathway inhibitors like NSC23766 trihydrochloride are valuable not only for mechanistic studies in cancer but also as key negative controls or pathway dissection tools in metabolic research (internal_article).

Limitations and Transferability

While the study presents robust evidence for the lactate-GPR81-FARP1-Rac1 axis in mouse skeletal muscle and human association datasets, several limitations warrant consideration:

• Most mechanistic data are derived from murine models and in vitro muscle cells; direct demonstration in human muscle tissue is limited (Cell Research, 2026).
• The use of pharmacological agents and overexpression systems, while informative, may not fully recapitulate physiological signaling dynamics.
• The interplay between this insulin-independent pathway and other regulatory mechanisms (e.g., AMPK, CaMK) during exercise or metabolic disease remains to be fully integrated.
• Translational application as a therapeutic strategy for diabetes or metabolic syndrome will require further validation in human clinical studies.

Nevertheless, the central finding—that Rac1 activation downstream of GPR81 can drive GLUT4 translocation without insulin—offers a credible new target for metabolic intervention and highlights the value of pathway-specific inhibitors for validating biological mechanisms.

Research Support Resources

For researchers aiming to dissect the Rac1 signaling pathway in metabolic or cancer models, NSC23766 trihydrochloride (SKU A1952) is a widely used Rac GTPase inhibitor. This compound selectively blocks Rac1 activation by interfering with its interaction with GEFs such as Trio and Tiam1, and has been validated in cell-based and in vivo studies as a tool for probing Rac1-dependent pathways (internal_article). When designing experiments to validate the lactate-GPR81-FARP1-Rac1 axis or to distinguish between insulin-dependent and -independent glucose uptake, NSC23766 trihydrochloride from APExBIO can serve as an effective negative control or pathway dissection agent. Researchers are advised to refer to published protocols and product documentation for details on optimal concentrations and storage conditions (workflow_recommendation).